After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Immunovant Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Immunovant Inc is $4.15B. A total of 2.11 million shares were traded on the day, compared to an average of 1.68M shares.
In the most recent transaction, Geffner Michael sold 2,595 shares of IMVT for 19.03 per share on Oct 22 ’25. After the transaction, the Chief Medical Officer now owns 217,958 company shares. In a previous transaction on Oct 22 ’25, Stout Jay S sold 2,520 shares at 19.03 per share. IMVT shares that Chief Technology Officer owns now total 200,814.
Among the insiders who sold shares, Geffner Michael disposed of 1,272 shares on Oct 08 ’25 at a per-share price of $16.30. This resulted in the Chief Medical Officer holding 220,553 shares of IMVT after the transaction. In another insider transaction, Stout Jay S sold 1,585 shares at $16.30 per share on Oct 08 ’25. Company shares held by the Chief Technology Officer now total 203,334.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, IMVT has a high of $32.10 and a low of $12.72.
As of this writing, IMVT has an earnings estimate of -$0.73 per share for the current quarter. EPS was calculated based on a consensus of 13.0 estimates, with a high estimate of -$0.59 per share and a lower estimate of -$0.8. The company reported an EPS of -$0.74 in the last quarter
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. IMVT’s latest balance sheet shows that the firm has $493.82M in Cash & Short Term Investments as of fiscal 2022. There were $2.36M in debt and $44.52M in liabilities at the time. Its Book Value Per Share was $3.56, while its Total Shareholder’s Equity was $469.82M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IMVT is Buy with a score of 4.44.
